Glucocorticoids in the control of neuroinflammation

Molecular and Cellular Endocrinology

Volumn 275, Issue 1-2, 2007, Pages 62-70

  Tischner, Denise ^a   Reichardt, Holger M ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Apoptosis; Blood brain barrier; Experimental autoimmune encephalomyelitis; Glucocorticoids; Multiple sclerosis

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; METHYLPREDNISOLONE;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLOOD BRAIN BARRIER; DIABETES MELLITUS; DNA BINDING; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERABILITY; GASTROINTESTINAL PAIN; HEADACHE; HOMEOSTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOCYTE MIGRATION; MOOD DISORDER; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TRANSCRIPTION INITIATION;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GLUCOCORTICOIDS; HUMANS; MULTIPLE SCLEROSIS; NEUROIMMUNOMODULATION;

EID: 34547858171     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2007.03.007     Document Type: Review

References (84)

1. Adams R.A., Bauer J., Flick M.J., Sikorski S.L., Nuriel T., Lassmann H., Degen J.L., and Akassoglou K. The fibrin-derived γ377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J. Exp. Med. 204 (2007) 571-582
2. Almawi W.Y., Beyhum H.N., Rahme A.A., and Rieder M.J. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J. Leukoc. Biol. 60 (1996) 563-572
3. Ballabh P., Braun A., and Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16 (2004) 1-13
4. Bartholome B., Spies C.M., Gaber T., Schuchmann S., Berki T., Kunkel D., Bienert M., Radbruch A., Burmester G.R., Lauster R., Scheffold A., and Buttgereit F. Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. FASEB J. 18 (2004) 70-80
5. Beato M., Herrlich P., and Schütz G. Steroid hormone receptors: many actors in search of a plot. Cell 83 (1995) 851-857
6. Beck R.W., Cleary P.A., Anderson Jr. M.M., Keltner J.L., Shults W.T., Kaufman D.I., Buckley E.G., Corbett J.J., Kupersmith M.J., Miller N.R., et al., The Optic Neuritis Study Group. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N. Engl. J. Med. 326 (1992) 581-588
7. Ben-Nun A., Wekerle H., and Cohen I.R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 11 (1981) 195-199
8. Bjartmar C., and Trapp B.D. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 14 (2001) 271-278
9. Boylan M.T., Crockard A.D., McDonnell G.V., Armstrong M.A., and Hawkins S.A. CD80 (B7-1) and CD86 (B7-2) expression in multiple sclerosis patients: clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone. J. Neurol. Sci. 167 (1999) 79-89
10. Chan J.R., Phillips II L.J., and Glaser M. Glucocorticoids and progestins signal the initiation and enhance the rate of myelin formation. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 10459-10464
11. Chen X., Murakami T., Oppenheim J.J., and Howard O.M. Differential response of murine CD4+ CD25+ and CD4+ CD25- T cells to dexamethasone-induced cell death. Eur. J. Immunol. 34 (2004) 859-869
12. Chen X., Oppenheim J.J., Winkler-Pickett R.T., Ortaldo J.R., and Howard O.M. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur. J. Immunol. 36 (2006) 2139-2149
13. Correale J., Arias M., and Gilmore W. Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects. J. Immunol. 161 (1998) 3365-3374
14. Diem R., Hobom M., Maier K., Weissert R., Storch M.K., Meyer R., and Bähr M. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J. Neurosci. 23 (2003) 6993-7000
15. Diem R., Sattler M.B., Merkler D., Demmer I., Maier K., Stadelmann C., Ehrenreich H., and Bähr M. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 128 (2005) 375-385
16. Elenkov I.J., and Chrousos G.P. Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol. Metab. 10 (1999) 359-368
17. Elovaara I., Kuusisto H., Paalavuo R., Sarkijarvi S., Lehtimaki T., Huhtala H., and Vilpo J. Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation. Acta Neurol. Scand. 113 (2006) 163-166
18. Elovaara I., Lalla M., Spare E., Lehtimaki T., and Dastidar P. Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS. Neurology 51 (1998) 1703-1708
19. Elovaara I., Ukkonen M., Leppakynnas M., Lehtimaki T., Luomala M., Peltola J., and Dastidar P. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Arch. Neurol. 57 (2000) 546-551
20. Engelhardt B. Molecular mechanisms involved in T cell migration across the blood-brain barrier. J. Neural. Transm. 113 (2006) 477-485
21. Erlacher M., Michalak E.M., Kelly P.N., Labi V., Niederegger H., Coultas L., Adams J.M., Strasser A., and Villunger A. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 106 (2005) 4131-4138
22. Fontoura P., Steinman L., and Miller A. Emerging therapeutic targets in multiple sclerosis. Curr. Opin. Neurol. 19 (2006) 260-266
23. Förster C., Silwedel C., Golenhofen N., Burek M., Kietz S., Mankertz J., and Drenckhan D. Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system. J. Physiol. 565 (2005) 475-486
24. Förster C., Waschke J., Burek M., Leers J., and Drenckhan D. Glucocorticoid effects on mouse microvascular endothelial barrier permeability are brain specific. J. Physiol. 573 (2006) 413-425
25. Friese M.A., and Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?. Brain 128 (2005) 1747-1763
26. Gayo A., Mozo L., Suarez A., Tunon A., Lahoz C., and Gutierrez C. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J. Neuroimmunol. 85 (1998) 122-130
27. Gelati M., Corsini E., Dufour A., Massa G., Giombini S., Solero C.L., and Salmaggi A. High-dose methylprednisolone reduces cytokine-induced adhesion molecules on human brain endothelium. Can. J. Neurol. Sci. 27 (2000) 241-244
28. Gold R., Linington C., and Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129 (2006) 1953-1971
29. Golde S., Coles A., Lindquist J.A., and Compston A. Decreased iNOS synthesis mediates dexamethasone-induced protection of neurons from inflammatory injury in vitro. Eur. J. Neurosci. 18 (2003) 2527-2537
30. Grauer O., Offenhausser M., Schmidt J., Toyka K.V., and Gold R. Glucocorticosteroid therapy in optic neuritis and multiple sclerosis. Evidence from clinical studies and practical recommendations. Nervenarzt 72 (2001) 577-589
31. Hafler D.A. Multiple sclerosis. J. Clin. Invest. 113 (2004) 788-794
32. Harkness K.A., Adamson P., Sussman J.D., Davies-Jones G.A., Greenwood J., and Woodroofe M.N. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 123 (2000) 698-709
33. Heck S., Bender K., Kullmann M., Gottlicher M., Herrlich P., and Cato A.C. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. EMBO J. 16 (1997) 4698-4707
34. Heck S., Kullmann M., Gast A., Ponta H., Rahmsdorf H.J., Herrlich P., and Cato A.C. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 13 (1994) 4087-4095
35. Hemmer B., Nessler S., Zhou D., Kieseier B., and Hartung H.P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2 (2006) 201-211
36. Herold M.J., McPherson K.G., and Reichardt H.M. Glucocorticoids in T cell apoptosis and function. Cell. Mol. Life Sci. 63 (2006) 60-72
37. Karlstedt K., Sallmen T., Eriksson K.S., Lintunen M., Couraud P.O., Joo F., and Panula P. Lack of histamine synthesis and down-regulation of H1 and H2 receptor mRNA levels by dexamethasone in cerebral endothelial cells. J. Cereb. Blood Flow. Metab. 19 (1999) 321-330
38. Kawakami N., Nagerl U.V., Odoardi F., Bonhoeffer T., Wekerle H., and Flügel A. Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion. J. Exp. Med. 201 (2005) 1805-1814
39. Kiefer R., and Kreutzberg G.W. Effects of dexamethasone on microglial activation in vivo: selective downregulation of major histocompatibility complex class II expression in regenerating facial nucleus. J. Neuroimmunol. 34 (1991) 99-108
40. Kleinert H., Euchenhofer C., Ihrig-Biedert I., and Forstermann U. Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-kappa B. Mol. Pharmacol. 49 (1996) 15-21
41. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., and Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177 (2006) 566-573
42. Leussink V.I., Jung S., Merschdorf U., Toyka K.V., and Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch. Neurol. 58 (2001) 91-97
43. Limbourg F.P., Huang Z., Plumier J.C., Simoncini T., Fujioka M., Tuckermann J., Schütz G., Moskowitz M.A., and Liao J.K. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J. Clin. Invest. 110 (2002) 1729-1738
44. Lu N.Z., and Cidlowski J.A. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol. Cell 18 (2005) 331-342
45. Luisi B.F., Xu W.X., Otwinowski Z., Freedman L.P., Yamamoto K.R., and Sigler P.B. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 352 (1991) 497-505
46. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schütz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., et al. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835-839
47. McCombe P.A., Nickson I., Tabi Z., and Pender M.P. Corticosteroid treatment of experimental autoimmune encephalomyelitis in the Lewis rat results in loss of V beta 8.2+ and myelin basic protein-reactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of V beta 8.2+ cells. J. Neuroimmunol. 70 (1996) 93-101
48. Migita K., Eguchi K., Kawabe Y., Nakamura T., Shirabe S., Tsukada T., Ichinose Y., Nakamura H., and Nagataki S. Apoptosis induction in human peripheral blood T lymphocytes by high-dose steroid therapy. Transplantation 63 (1997) 583-587
49. Milligan N.M., Newcombe R., and Compston D.A. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. 1. Clinical effects. J. Neurol. Neurosurg. Psychiatry 50 (1987) 511-516
50. Mirowska-Guzel D.M., Kurowska K., Skierski J., Koronkiewicz M., Wicha W., Kruszewska J., Czlonkowski A., and Czlonkowska A. High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse. J. Neuroimmunol. 176 (2006) 134-140
51. Moreira M.A., Tilbery C.P., Monteiro L.P., Teixeira M.M., and Teixeira A.L. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Acta Neurol. Scand. 114 (2006) 109-113
52. Murray T.J. Diagnosis and treatment of multiple sclerosis. BMJ 332 (2006) 525-527
53. Navarro J., Aristimuno C., Sanchez-Ramon S., Vigil D., Martinez-Gines M.L., Fernandez-Cruz E., and de Andres C. Circulating dendritic cells subsets and regulatory T-cells at multiple sclerosis relapse: differential short-term changes on corticosteroids therapy. J. Neuroimmunol. 176 (2006) 153-161
54. Nguyen K.B., McCombe P.A., and Pender M.P. Increased apoptosis of T lymphocytes and macrophages in the central and peripheral nervous systems of Lewis rats with experimental autoimmune encephalomyelitis treated with dexamethasone. J. Neuropathol. Exp. Neurol. 56 (1997) 58-69
55. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 343 (2000) 938-952
56. Paul C., and Bolton C. Inhibition of blood-brain barrier disruption in experimental allergic encephalomyelitis by short-term therapy with dexamethasone or cyclosporin A. Int. J. Immunopharmacol. 17 (1995) 497-503
57. Pender M.P., McCombe P.A., Yoong G., and Nguyen K.B. Apoptosis of alpha beta T lymphocytes in the nervous system in experimental autoimmune encephalomyelitis: its possible implications for recovery and acquired tolerance. J. Autoimmun. 5 (1992) 401-410
58. Pozzilli C., Marinelli F., Romano S., and Bagnato F. Corticosteroids treatment. J. Neurol. Sci. 223 (2004) 47-51
59. Purton J.F., Monk J.A., Liddicoat D.R., Kyparissoudis K., Sakkal S., Richardson S.J., Godfrey D.I., and Cole T.J. Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death. J. Immunol. 173 (2004) 3816-3824
60. Reder A.T., Thapar M., and Jensen M.A. A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis: implications for treatment of inflammatory brain disease. Neurology 44 (1994) 2289-2294
61. Redford E.J., Kapoor R., and Smith K.J. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 120 (1997) 2149-2157
62. Reichardt H.M. Immunomodulatory activities of glucocorticoids: insights from transgenesis and gene targeting. Curr. Pharm. Des. 10 (2004) 2797-2805
63. Reichardt H.M., Gold R., and Lühder F. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. Expert Rev. Neurother. 6 (2006) 1657-1670
64. Reichardt H.M., Kaestner K.H., Tuckermann J., Kretz O., Wessely O., Bock R., Gass P., Schmid W., Herrlich P., Angel P., and Schütz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93 (1998) 531-541
65. Rivers T.M., Sprunt D.H., and Berry G.P. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. (1933) 58
66. Romero I.A., Radewicz K., Jubin E., Michel C.C., Greewood J., Couraud P.O., and Adamson P. Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. Neurosci. Lett. 26 (2003) 112-116
67. Rosenberg G.A., Dencoff J.E., Correa Jr. N., Reiners M., and Ford C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46 (1996) 1626-1632
68. Schmidt J., Gold R., Schonrock L., Zettl U.K., Hartung H.P., and Toyka K.V. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 123 (2000) 1431-1441
69. Screpanti I., Morrone S., Meco D., Santoni A., Gulino A., Paolini R., Crisanti A., Mathieson B.J., and Frati L. Steroid sensitivity of thymocyte subpopulations during intrathymic differentiation. Effects of 17 beta-estradiol and dexamethasone on subsets expressing T cell antigen receptor or IL-2 receptor. J. Immunol. 142 (1989) 3378-3383
70. Sloka J.S., and Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult. Scler. 11 (2005) 425-432
71. Smith T., Schmied M., Hewson A.K., Lassmann H., and Cuzner M.L. Apoptosis of T cells and macrophages in the central nervous system of intact and adrenalectomized Lewis rats during experimental allergic encephalomyelitis. J. Autoimmun. 9 (1996) 167-174
72. Song I.H., and Buttgereit F. Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol. Cell. Endocrinol. 246 (2006) 142-146
73. Sorensen T.L., Trebst C., Kivisakk P., Klaege K.L., Majmudar A., Ravid R., Lassmann H., Olsen D.B., Strieter R.M., Ransohoff R.M., and Sellebjerg F. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J. Neuroimmunol. 127 (2002) 59-68
74. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
75. Stoecklin E., Wissler M., Moriggl R., and Groner B. Specific DNA binding of Stat5, but not of glucocorticoid receptor, is required for their functional cooperation in the regulation of gene transcription. Mol. Cell. Biol. 17 (1997) 6708-6716
76. Swanborg R.H. Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity. Immunol. Rev. 184 (2001) 129-135
77. Tabi Z., McCombe P.A., and Pender M.P. Apoptotic elimination of V beta 8.2+ cells from the central nervous system during recovery from experimental autoimmune encephalomyelitis induced by the passive transfer of V beta 8. 2+ encephalitogenic T cells. Eur. J. Immunol. 24 (1994) 2609-2617
78. Tischner D., Weishaupt A., van den Brandt J., Müller N., Beyersdorf N., Ip C.W., Toyka K.V., Hünig T., Gold R., Kerkau T., and Reichardt H.M. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain 129 (2006) 2635-2647
79. Tuckermann J.P., Kleiman A., McPherson K.G., and Reichardt H.M. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit. Rev. Clin. Lab. Sci. 42 (2005) 71-104
80. van den Brandt J., Lühder F., McPherson K.G., de Graaf K.L., Tischner D., Wiehr S., Herrmann T., Weissert R., Gold R., and Reichardt H.M. Enhanced glucocorticoid receptor signalling in T cells impacts thymocyte apoptosis and adaptive immune responses. Am. J. Pathol. 170 (2007) 1041-1053
81. Vanderheyde N., Verhasselt V., Goldman M., and Willems F. Inhibition of human dendritic cell functions by methylprednisolone. Transplantation 67 (1999) 1342-1347
82. Wang D., Müller N., McPherson K.G., and Reichardt H.M. Glucocorticoids engage different signal transduction pathways to induce apoptosis in thymocytes and mature T cells. J. Immunol. 176 (2006) 1695-1702
83. Wang H.Y., Matsui M., Araya S., Onai N., Matsushima K., and Saida T. Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis. J. Neurol. Sci. 216 (2003) 61-66
84. Webster J.C., Jewell C.M., Bodwell J.E., Munck A., Sar M., and Cidlowski J.A. Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J. Biol. Chem. 272 (1997) 9287-9293